HOUSTON, May 7, 2019 /PRNewswire/ -- Marker Therapeutics,
Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company
specializing in the development of next-generation T cell-based
immunotherapies for the treatment of hematological malignancies and
solid tumor indications, today announced that its President
and Chief Executive Officer, Peter L.
Hoang, will be presenting at the 2019 Bank of America
Merrill Lynch Health Care Conference on Thursday, May 16, 2019.
Presentation Details
Date: Thursday, May 16, 2019
Time: 10:40 a.m. PDT
Location: Encore Hotel, Las Vegas,
NV
A live webcast of the presentation will be available in the
investors section of the company's website at
www.markertherapeutics.com and will be available for replay two
hours following the event.
About Marker Therapeutics,
Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
Once infused into patients, this population of T cells attacks
multiple tumor targets and acts to activate the patient's immune
system to produce broad spectrum anti-tumor activity. Because
Marker does not genetically engineer its T cells, when compared to
current engineered CAR-T and TCR-based approaches, its products (i)
are significantly less expensive and easier to manufacture, (ii)
appear to be markedly less toxic, and (iii) are associated with
meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling therapeutic product
profile, as compared to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase II clinical
trials. In parallel, we are developing a proprietary DNA expression
technology named PolyStart™ that can enhance the ability of the
immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904)
862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us
on Facebook.
Forward-Looking Statement
Disclaimer
This
release contains forward-looking statements for purposes of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research and development activities
relating to our non-engineered multi-tumor antigen specific T cell
therapies; our TPIV200 and TPIV100/110 programs and our PolyStart™
program; the effectiveness of these programs or the possible range
of application and potential curative effects and safety in the
treatment of diseases; and, the timing and success of our clinical
trials, as well as clinical trials conducted by our collaborators.
Forward-looking statements are by their nature subject to risks,
uncertainties and other factors which could cause actual results to
differ materially from those stated in such statements. Such risks,
uncertainties and factors include, but are not limited to the risks
set forth in the Company's most recent Form 10-K, 10-Q and other
SEC filings which are available through EDGAR at www.sec.gov. The
Company assumes no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-300845554.html
SOURCE Marker Therapeutics, Inc.